Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
about
Translating pharmacogenomics: challenges on the road to the clinicChapter 7: PharmacogenomicsPharmacogenetics of beta-blockersPersonalized medicine and treatment approaches in hypertension: current perspectivesMechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersPharmacogenetics and anaesthesia: the value of genetic profilingClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationPharmacogenomics of hypertension and heart diseasePharmacogenomics and drug response in cardiovascular disordersReal-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilolMultiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival.GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.The Pharmacogenomics of Anti-Hypertensive TherapyPharmacogenetics of antihypertensive treatment: detailing disciplinary dissonanceBeta-blocker pharmacogenetics in heart failure.Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathwaysPolymorphisms in α- and β-Adrenergic Receptor Genes, Hypertension, and Obstructive Sleep Apnea: The Skaraborg Sleep Study.G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockersWhy do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study.Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography.Pharmacogenomics: the genetics of variable drug responses.PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individualsCardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directionsImpact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.Progress and future aspects in genetics of human hypertensionCardiovascular pharmacogenomicsGenetic variation, β-blockers, and perioperative myocardial infarction.The functional significance of genetic variation within the beta-adrenoceptor.Pharmacogenomics of adrenoceptors.A case for pharmacogenomics in management of cardiac arrhythmias.Emerging strategies and applications of pharmacogenomicsG protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targetsPharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenetics of chronic cardiovascular drugs: applications and implications.Neurohumoral activation in heart failure: the role of adrenergic receptors.Hypertension pharmacogenomics: in search of personalized treatment approaches
P2860
Q21092371-986EB117-3DF1-4769-8CB3-6BE83C903507Q21563496-64BC521E-FE91-4FF3-9050-725322110CB4Q24644448-FD4ED54E-4CBE-4719-81F6-C25FF10EE4E8Q26751135-F58B8B01-88E3-4EA2-BCE0-8612974A7AAAQ26753129-8E73E516-56EB-4F62-B4D7-30F32A2DE289Q26859221-A6652F78-1335-4F33-9F56-17B44D78318CQ27011524-7199A343-0B58-4BF6-87DE-3CF00D653BA7Q27015722-D7F74AC4-3E77-4857-857B-17ABAE6C3E47Q28171051-9BA878E6-CADC-44FA-B53E-2B8BAA03B386Q30478644-1DC4323C-FA22-424C-83F7-C92ECDC02FF8Q33378995-B5B92861-1485-4257-BB12-C08153E7D690Q33646237-06ABDD55-97AB-44DE-BA3F-DF837720AA0AQ33664144-E57A65D2-B5A2-43B7-89D0-BA9018193119Q33776918-CF07168B-4C39-4CFF-8AA7-8CEC4F330C57Q33778169-B59DC12E-A0D4-4244-9E01-39B8F819EBCFQ33923776-F51BDC95-D762-455C-A64A-657C71EB8F07Q34170701-41BEFBFF-9578-4AA8-9FEA-F7A114618F15Q34735239-068AAF0A-1288-4EB1-9783-6A0CA60B391DQ34747512-5BA6499D-50B9-4405-9D50-B1AFC90E210FQ34766294-4823B644-AC4D-4115-8A02-47AE7D62CBB4Q34792411-88C10861-CE51-45CD-B58E-B300CC14C24FQ34976915-8DB9FAF4-7615-4CA5-9549-E32D5702F2D2Q34994915-E12DCEF8-E87F-4980-81C6-9F494466B39DQ34997022-14AF350A-D171-4DD5-99DD-93F9CC982F53Q35033003-4E02A6A3-9DA6-40D6-AB52-677CBA2BDC2BQ35046547-A3A35B69-6C42-4FBF-B3F1-B34CF121FE97Q35202339-77D26D9B-6B1E-4932-A7A4-3C9CF45237E5Q35447163-8BA0F76A-1DCB-4A80-A13F-7E7B3FA6728BQ35580952-0E5388E3-7422-4DF3-B8F7-FBAAF8A36CE1Q35826772-9F65402F-A8BD-4999-8D9F-8ECD08F1BD25Q35911140-AEA9A75D-A01C-4B1E-9E8C-9809EA2C7757Q35914690-6AF727EC-8A75-439B-A77F-6B3EB2691BDAQ35988130-CC0FBE12-CDBF-419C-BE1C-DE80DD71394FQ36291684-E4A23158-36C5-41D8-9664-B9DEB2926C85Q36316001-1962FFE9-FD01-4B20-95F7-AD098B9C1343Q36326202-9F868703-918E-4384-A369-58A4B59E800BQ36441521-7C2FCFE2-28D2-4E92-B6FE-C3AB9A4548F0Q36543128-2BE8B651-69ED-4835-8FE3-B45AD3AF867CQ36579463-DB2DF021-C76B-48C6-B8A3-1A6DBDBCCFA0Q36652960-FA1A9CAC-6684-4B8F-BA14-575E6C297321
P2860
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
@en
type
label
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
@en
prefLabel
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
@en
P2093
P1476
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
@en
P2093
Brian J Puckett
Daniel F Pauly
Hossein N Yarandi
Issam Zineh
Julie A Johnson
Susan P McGorray
P356
10.1016/S0009-9236(03)00068-7
P407
P577
2003-07-01T00:00:00Z